Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25023293 | 1.00 | CRBN (0.66) | CRBNDDB1NPY2R | |
| SCHEMBL25845569 | 0.96 | DDB1 (0.61) | CRBNDDB1 | |
| SCHEMBL30207463 | 0.90 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL23783334 | 0.90 | CRBN (0.55) | CRBNDDB1 | |
| SCHEMBL26329796 | 0.89 | DDB1 (0.68) | CRBNDDB1 | |
| SCHEMBL26329799 | 0.89 | DDB1 (0.68) | CRBNDDB1 | |
| SCHEMBL29535454 | 0.89 | DDB1 (0.68) | CRBNDDB1 | |
| SCHEMBL25027239 | 0.89 | DDB1 (0.68) | CRBNDDB1 | |
| SCHEMBL25585868 | 0.88 | DDB1 (0.63) | CRBNDDB1 | |
| SCHEMBL29179837 | 0.88 | DDB1 (0.69) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885NPY2R 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.